Daiichi Sankyo and Merck Launch Phase 3 IDeate-Esophageal01 Trial of Ifinatamab Deruxtecan in Advanced Esophageal Squamous Cell Carcinoma Daiichi Sankyo and Merck have officially initiated dosing in their pivotal Phase 3 clinical trial, named IDeate-Esophageal01, marking a significant step forward…
One World for Health: Inside the 78th World Health Assembly and the Future of Global Public Health From May 19 to 27, 2025, Geneva, Switzerland, will once again become the epicenter of global health governance as it hosts the Seventy-eighth…
WHO and Universal Postal Union Launch Global Initiative to Expand Access to Eye Care Through Postal Networks In a groundbreaking move to address the global burden of vision impairment, the World Health Organization (WHO) has announced a strategic partnership with…
30 Years of Progress: Mobilizing the Health Sector to End Violence Against Women and Girls In the three decades since the landmark Beijing Platform for Action on Women was adopted in 1995, the world has made significant strides in recognizing…
BioMarin Bolsters Enzyme Therapy Portfolio with $270 Million Acquisition of Rare Disease Specialist Inozyme Pharma BioMarin Pharmaceutical, a leading biotech company focused on rare diseases and enzyme replacement therapies, announced on Friday that it is acquiring Inozyme Pharma, a clinical-stage…
Incyte’s Zynyz Secures First-Line Approval in Anal Cancer, Marking a Milestone for PD-1 Therapy in Rare Tumor Type In a significant development for the treatment of a rare and underserved cancer type, Incyte Corporation announced on Thursday that the U.S.…
Global Youth Scientists Shine at 75th Regeneron ISEF, Sharing Over $9 Million in Prizes In a celebration of youthful brilliance, scientific curiosity, and international collaboration, the 75th Annual Regeneron International Science and Engineering Fair (ISEF) awarded over $9 million in…
European Commission Grants Approval to Bristol Myers Squibb’s Perioperative Opdivo Regimen for Resectable, High-Risk NSCLC with PD-L1 Expression ≥1% Bristol Myers Squibb has announced that the European Commission (EC) has formally approved a new perioperative treatment regimen involving its immune…
CSL Behring’s Broadmeadows Plasma Facility Wins Prestigious 2025 ISPE Facility of the Year Award for Pharma 4.0 Innovation CSL Behring has earned global recognition for its trailblazing approach to pharmaceutical manufacturing, with its state-of-the-art plasma processing facility in Broadmeadows, Victoria,…
Gilead and Kite Set to Showcase Transformative Oncology Data at 2025 ASCO and EHA Conferences, Highlighting Advances in Breast Cancer, Multiple Myeloma, and Glioblastoma Gilead Sciences,and its Kite subsidiary are poised to deliver a powerful presence at two of the…
Merck’s KEYTRUDA-Based Regimen Achieves Major Milestone in Phase 3 KEYNOTE-B96 Trial for Platinum-Resistant Ovarian Cancer Merck & Co., Inc. (NYSE: MRK), operating as MSD outside the United States and Canada, announced a significant advancement in the treatment of platinum-resistant recurrent…
GSK Acquires Phase III-Ready Efimosfermin for $1.2 Billion in Bid to Transform Steatotic Liver Disease Treatment GSK has announced a major strategic acquisition in the field of hepatology, entering into a definitive agreement to acquire efimosfermin alfa, a potential best-in-class…